PET Imaging Studies in Rhesus Monkey with the Cannabinoid-1 (CB1) Receptor Ligand [11C]CB-119
暂无分享,去创建一个
Amy Vanko | H. Donald Burns | Christine Ryan | Richard Hargreaves | James Jewell | Brett Connolly | Terence G. Hamill | B. Connolly | H. Burns | R. Hargreaves | W. Hagmann | T. Hamill | W. Eng | C. Ryan | Amy Vanko | James P. Jewell | L. Lin | M. Goulet | T. Fong | Linus S. Lin | William Hagmann | Ping Liu | Sandra Sanabria | WaiSi Eng | Tung M. Fong | Mark T. Goulet | S. Sanabria | Ping Liu
[1] M. Herkenham,et al. Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[2] Sandra M. Sanabria-Bohórquez,et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. , 2008, Cell metabolism.
[3] Arman Rahmim,et al. 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] Christer Halldin,et al. The PET Radioligand [11C]MePPEP Binds Reversibly and with High Specific Signal to Cannabinoid CB1 Receptors in Nonhuman Primate Brain , 2008, Neuropsychopharmacology.
[5] Patrick Dupont,et al. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor , 2007, Proceedings of the National Academy of Sciences.
[6] Jeih-San Liow,et al. Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents , 2008, NeuroImage.
[7] L. V. D. van der Ploeg,et al. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. , 2006, Journal of medicinal chemistry.
[8] N. Volkow,et al. In vivo imaging of the brain cannabinoid receptor. , 2002, Chemistry and physics of lipids.
[9] H. Burns,et al. Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use. , 2007, Journal of medicinal chemistry.
[10] R. Faull,et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain , 1997, Neuroscience.
[11] Daniel P. Holt,et al. Synthesis of 1‐(2,4‐dichlorophenyl)‐4‐cyano‐5‐(4‐[11C]methoxyphenyl)‐N‐(piperidin‐1‐yl)‐1H‐pyrazole‐3‐carboxamide ([11C]JHU75528) and 1‐(2‐bromophenyl)‐4‐cyano‐5‐(4‐[11C]methoxyphenyl)‐N‐(piperidin‐1‐yl)‐1H‐pyrazole‐3‐carboxamide ([11C]JHU75575) as potential radioligands for PET imaging of cerebral , 2006 .
[12] S. Glaser,et al. Imaging of the brain cannabinoid system. , 2005, Handbook of experimental pharmacology.
[13] Yue Feng,et al. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. , 2006, Journal of medicinal chemistry.